WuXi's small molecule CDMO STA is adding a drug development services operation as it builds itself into an end-to-end CDMO.
GlaxoSmithKline plans to unload some marginal businesses and make other cuts that it says will cost about 320 manufacturing jobs in its home country.
India’s Alembic Pharma said the facility will manufacture 60 million tablets and capsules and about 20 million vials of liquid concentrates.
The FDA has issued a warning letter to India's Vista Pharmaceuticals after it found it using corroded equipment.
AGC Asahi Glass, which bought CMC Biologics this year, will make its Seattle, Washington, area operation the headquarters of its drug business.
Gilead hit with revived lawsuit claiming it sourced a key HIV drug ingredient from an unapproved Chinese manufacturer.
Oxford BioMedica has a new deal for up to $100 million to provide the lentiviral vectors for the personalized CAR-T treatment Novartis is developing.
CDMO Patheon is investing $45 million in four sites that stretch from the West Coast of the U.S. to Italy.
BASF will expand its ibuprofen API capacity with a new plant in Ludwigshafen, Germany, and expansion of a facility in Texas.
An FDA warning letter has been issued to a CMO that made belladonna-treated teething products that the agency warned may cause seizures in infants.